Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08329's Days Inventory is ranked better than 81.54% of 921
companies
in the Drug Manufacturers industry
Industry Median: 165.34
vs HKSE:08329: 93.94
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shenzhen Neptunus Interlong Bio-Technique Co's Inventory Turnover for the
six
months ended in Jun. 2026 was 1.89.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shenzhen Neptunus Interlong Bio-Technique Co's Inventory-to-Revenue for the
six
months ended in Jun. 2026 was 0.37.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Shenzhen Neptunus Interlong Bio-Technique Co's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shenzhen Neptunus Interlong Bio-Technique Co's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Shenzhen Neptunus Interlong Bio-Technique Co Days Inventory Related Terms
Shenzhen Neptunus Interlong Bio-Technique Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co Days Inventory Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Days Inventory vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Days Inventory of 48.31 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 58% below median its historical median of 114.99. Over the past decade, Shenzhen Neptunus Interlong Bio-Technique Co's Days Inventory has ranged from 93.94 to 148.94. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #170 out of 921 companies in the Drug Manufacturers industry, placing it in the top 18.5%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Days Inventory too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Days Inventory of 48.31 is 58% below median its 10-year median of 114.99. Over the past 10 years, this metric has ranged from a low of 93.94 to a high of 148.94. The Drug Manufacturers industry median Days Inventory is 165.34. Shenzhen Neptunus Interlong Bio-Technique Co's value of 48.31 is 70.8% below this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #170 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shenzhen Neptunus Interlong Bio-Technique Co has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #170 out of 921 companies for Days Inventory. This places Shenzhen Neptunus Interlong Bio-Technique Co in the top 19% of its industry — outperforming the majority of peers. The industry median Days Inventory is 165.34. Shenzhen Neptunus Interlong Bio-Technique Co's value of 48.31 is 70.8% below this benchmark. Historically, Shenzhen Neptunus Interlong Bio-Technique Co's own Days Inventory has ranged from 93.94 to 148.94 over the past decade. While the company's 10-year median is 114.99 vs. the industry median of 165.34, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.34, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current Days Inventory of 48.31 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Days Inventory is 48.31, which is 58% below median its own 10-year median of 114.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.11 — trading 25% below its estimated fair value. The current Days Inventory is 48.31, which is 58% below median its 10-year median of 114.99 and 70.8% below the Drug Manufacturers industry median of 165.34. Shenzhen Neptunus Interlong Bio-Technique Co's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Days Inventory is 48.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 25% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.
Key valuation signals for HKSE:08329:
Days Inventory: 48.31 (58% below median its 10-year median of 114.99)
GF Value™: HK$0.14 vs. price of HK$0.11 (25% below fair value)
Industry Position: 70.8% below the Drug Manufacturers median (#170 of 921)
No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score
Get the complete analysis for HKSE:08329
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
